At the 14th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, hosted in Boston from November 9-12, 2021, Signant’s renowned Alzheimer’s disease experts and CNS thought leaders presented several scientific posters. Their original research explored a range of topics, including cultural influences on CDR and MMSE scores as well as the factors creating variances in screening and baseline scores. The posters reflect Signant’s deep therapeutic experience in Alzheimer’s disease, our powerful SmartSignals solutions, and our commitment to collaborative drug discovery and medical research innovation.

Peruse the posters below and meet our CNS experts.

Signant Health

Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently generate quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 20 years, over 400 sponsors and CROs of all sizes – including all of Top 20 pharma – have trusted Signant Health solutions for remote and site-based eCOA, eConsent, IRT, supply chain management, and data quality analytics.

Recent Posts

Scientific Advisory

11 Perspectives on the Present and Future of Clinical Development

Learn more

Clinical Supplies

Consider Patients First in Direct-to-Patient Trial Designs

Learn more

eCOA

Clinical Viewpoints Episode 1 Recap – Optimizing Pediatric Trials to Generate High-Quality Data

Learn more

eCOA

Webinar Recap: Decentralized by Design-Optimizing Trials for Remote Conduct

Learn more

eCOA

Trial Optimization as the Focus for Decentralized Methods

Learn more